8 research outputs found
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection
Receptor for advanced glycation end products (RAGE) protein expression in lung tissue from individual RAGE(lanes 1 to 3), RAGE(lanes 4 to 6), and RAGE(lanes 7 to 9) animals
<p><b>Copyright information:</b></p><p>Taken from "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection"</p><p>http://ccforum.com/content/11/6/R122</p><p>Critical Care 2007;11(6):R122-R122.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2246216.</p><p></p> Actin was used to demonstrate equal loading
Lethality from cecal ligation and puncture (CLP) is decreased in BALB/c mice administered an anti-RAGE monoclonal antibody (mAb)
<p><b>Copyright information:</b></p><p>Taken from "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection"</p><p>http://ccforum.com/content/11/6/R122</p><p>Critical Care 2007;11(6):R122-R122.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2246216.</p><p></p> The Kaplan-Meier survival analysis following CLP compares anti-RAGE mAb-treated animals given 7.5 mg/kg (= 15) or 15 mg/kg (= 15) intravenously 30 to 60 minutes before CLP with serum control animals (= 15). The group given 15 mg/kg had a significantly greater survival than the group given 7.5 mg/kg (< 0.05) or serum control (< 0.001). RAGE, receptor for advanced glycation end products
Delayed administration of the anti-RAGE antibody is protective in cecal ligation and puncture (CLP)
<p><b>Copyright information:</b></p><p>Taken from "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection"</p><p>http://ccforum.com/content/11/6/R122</p><p>Critical Care 2007;11(6):R122-R122.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2246216.</p><p></p> The Kaplan-Meier survival analysis following CLP in BALB/c mice compares delayed anti-RAGE monoclonal antibody (mAb) treatment given at various time intervals after CLP with serum control. Each group had a significantly greater survival than the control group (< 0.01), except for the 36-hour delayed treatment group (= 0.12). RAGE, receptor for advanced glycation end products
Modulation of receptor for advanced glycation end products (RAGE) protects mice from the effects of cecal ligation and puncture (CLP)
<p><b>Copyright information:</b></p><p>Taken from "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection"</p><p>http://ccforum.com/content/11/6/R122</p><p>Critical Care 2007;11(6):R122-R122.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2246216.</p><p></p> Kaplan-Meier survival analysis following CLP comparing wild-type RAGE129SvEvBrd mice (= 15), RAGEmice (= 15), RAGEmice (= 23), and anti-RAGE monoclonal antibody-treated (15 mg/kg intravenously 30 to 60 minutes before CLP) wild-type mice (= 15). < 0.001 for each group in comparison with the wild-type CLP control group. Sham surgery-treated wild-type 129SvEvBrd mice (= 5) were used as an additional control group. WT, wild-type
Inhibition or deletion of receptor for advanced glycation end products (RAGE) does not disrupt the host mechanism for clearance of
<p><b>Copyright information:</b></p><p>Taken from "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection"</p><p>http://ccforum.com/content/11/6/R122</p><p>Critical Care 2007;11(6):R122-R122.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2246216.</p><p></p> Quantitative levels of in organ samples (liver and spleen, = 10 per group) 48 hours after an intraperitoneal injection of 10colony-forming units (CFU) per animal (< 0.001 anti-tumor necrosis factor [TNF] monoclonal antibody [mAb] group versus all other groups)